免疫グロブリン融合タンパク質の世界市場レポート2025年

免疫グロブリン融合タンパク質の市場規模は今後数年で急成長が見込まれます。2029年には複合年間成長率（CAGR）13.7%で768億9,000万米ドルに成長します。予測期間に予測される成長は、高齢者人口の増加、融合タンパク質を含む臨床試験の拡大、個別化医療に対する需要の高まり、希少疾病用医薬品に対する規制当局の支援、在宅免疫療法治療の増加などに起因しています。この期間の主な動向としては、皮下製剤へのシフト、タンパク質設計におけるAIの統合、二重特異性融合タンパク質の開発、製薬企業とバイオテクノロジー企業の提携、タンパク質工学の進歩などが挙げられます。

自己免疫疾患の有病率の上昇は、今後の免疫グロブリン融合タンパク質市場の成長を促進すると予想されます。自己免疫疾患は、身体の免疫系が誤って自身の健康な細胞や組織を攻撃する疾患です。このような有病率の増加は、主に遺伝的素因と環境要因の組み合わせによって引き起こされ、遺伝的な遺伝子は個人をより脆弱にし、感染症やライフスタイルなどの誘因はこれらの疾患の発症に寄与します。免疫グロブリン融合タンパク質は、免疫反応を調節して炎症を減少させ、免疫系が身体の組織を攻撃するのを防ぐことにより、自己免疫疾患の管理を助ける。例えば、2024年11月、ドイツを拠点とする組織であるVersorgungsatlas.deのデータによると、2022年、7,324万1,305人の被保険者のうち、630万4,340人が少なくとも1つの自己免疫疾患と診断され、生の有病率は8.61％でした。このように、自己免疫疾患の有病率の増加が免疫グロブリン融合タンパク質市場の拡大に拍車をかけています。

免疫グロブリン融合タンパク質市場の主要企業は、治療効果の向上や複数の疾患経路を標的とすることを目的とした二特異性抗体融合タンパク質のような革新的な製品を生み出すための臨床試験の実施に注力しています。二重特異性抗体融合タンパク質は、2つの異なる標的を同時に結合できる遺伝子工学的に設計された分子であり、免疫細胞を腫瘍細胞に近づけたり、複数の疾患経路を同時に遮断することで標的治療を強化します。例えば、2025年2月、中国に本社を置くバイオテクノロジー企業Innovent Biologics, Inc.は、進行性固形がんを対象とした二重特異性抗体融合タンパク質IBI343について、米国食品医薬品局（FDA）から2回目のファスト・トラック指定（FTD）を受けた。IBI343は、腫瘍関連抗原と免疫エフェクター細胞に同時に作用し、抗腫瘍免疫応答の精度と強度を向上させるよう設計されています。今回の指定により、IBI343の臨床開発と規制当局による評価が加速され、がん領域における重要なアンメット・メディカル・ニーズを満たす可能性が強調されるものと期待されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の免疫グロブリン融合タンパク質：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の免疫グロブリン融合タンパク質市場：成長率分析
• 世界の免疫グロブリン融合タンパク質市場の実績：規模と成長, 2019-2024
• 世界の免疫グロブリン融合タンパク質市場の予測：規模と成長, 2024-2029, 2034F
• 世界の免疫グロブリン融合タンパク質：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の免疫グロブリン融合タンパク質市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• ポリクローナル抗体
• 二重特異性抗体
• 組み換え抗体
• 世界の免疫グロブリン融合タンパク質市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫抑制薬
• 免疫刺激薬
• 世界の免疫グロブリン融合タンパク質市場投与方法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内
• 皮下
• 筋肉内
• 世界の免疫グロブリン融合タンパク質市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 自己免疫疾患
• 眼疾患
• 糖尿病
• 血友病
• 世界の免疫グロブリン融合タンパク質市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 調査機関
• 世界の免疫グロブリン融合タンパク質市場モノクローナル抗体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヒトモノクローナル抗体
• ヒト化モノクローナル抗体
• キメラモノクローナル抗体
• マウスモノクローナル抗体
• 世界の免疫グロブリン融合タンパク質市場ポリクローナル抗体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 動物由来ポリクローナル抗体
• ヒト由来ポリクローナル抗体
• 組み換えポリクローナル抗体
• 世界の免疫グロブリン融合タンパク質市場二重特異性抗体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• タンデムシングルチェーン可変フラグメント
• 二重可変ドメイン抗体
• 二重特異性T細胞エンゲージャー（BiTE）
• 二重親和性再標的化抗体
• 世界の免疫グロブリン融合タンパク質市場、組換え抗体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• フラグメント抗体
• 完全長組み換え抗体
• 抗体薬物複合体（ADC）
• 改変抗体ドメイン

第7章 地域別・国別分析

• 世界の免疫グロブリン融合タンパク質市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の免疫グロブリン融合タンパク質市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 免疫グロブリン融合タンパク質市場：競合情勢
• 免疫グロブリン融合タンパク質市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Gilead Sciences Inc.
• Eli Lilly and Company
• Amgen Inc.
• Teva Pharmaceutical Industries Limited
• Regeneron Pharmaceuticals Inc.
• Sobi
• 3SBio Inc.
• Innovent Biologics Inc.
• Chengdu Kanghong Pharmaceutical Group Co. Ltd.
• Samsung Bioepis Co. Ltd.
• Proteintech Group Inc.
• KRISHGEN Biosystems
• Abnova（Taiwan）Corporation
• Celgen Biopharma Inc.
• Chimerigen Laboratories LLC

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 免疫グロブリン融合タンパク質市場2029：新たな機会を提供する国
• 免疫グロブリン融合タンパク質市場2029：新たな機会を提供するセグメント
• 免疫グロブリン融合タンパク質市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

An immunoglobulin fusion protein is a biologically engineered molecule formed by combining the functional domain of a target protein or peptide with the constant region of an immunoglobulin (antibody). This fusion improves the stability, half-life, and solubility of the target protein and can enhance its therapeutic effectiveness by utilizing the immune system's natural processes.

The primary types of immunoglobulin fusion proteins include monoclonal antibodies, polyclonal antibodies, bispecific antibodies, and recombinant antibodies. Monoclonal antibodies are laboratory-engineered proteins designed to specifically target and neutralize particular pathogens by imitating the body's immune response. The drug classes include immunosuppressive and immunostimulatory drugs. These proteins are delivered via different methods such as intravenous, subcutaneous, and intramuscular injections. They are applied in treating various conditions like autoimmune diseases, eye disorders, diabetes, and hemophilia. The main end users consist of hospitals, clinics, and research institutions.

The immunoglobulin fusion protein market research report is one of a series of new reports from The Business Research Company that provides immunoglobulin fusion protein market statistics, including the immunoglobulin fusion protein industry global market size, regional shares, competitors with the immunoglobulin fusion protein market share, detailed immunoglobulin fusion protein market segments, market trends, and opportunities, and any further data you may need to thrive in the immunoglobulin fusion protein industry. This immunoglobulin fusion protein market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The immunoglobulin fusion proteins market size has grown rapidly in recent years. It will grow from $40.39 billion in 2024 to $46.05 billion in 2025 at a compound annual growth rate (CAGR) of 14.0%. The growth during the historic period is due to the rising prevalence of autoimmune diseases, increased adoption of biologics, higher demand for targeted therapies, enhanced diagnostic capabilities, and greater investment in biologics research and development.

The immunoglobulin fusion proteins market size is expected to see rapid growth in the next few years. It will grow to $76.89 billion in 2029 at a compound annual growth rate (CAGR) of 13.7%. The growth projected for the forecast period can be attributed to the increasing geriatric population, expansion of clinical trials involving fusion proteins, rising demand for personalized medicine, regulatory support for orphan drugs, and the increase in home-based immunotherapy treatments. Key trends during this period include a shift toward subcutaneous formulations, the integration of AI in protein design, the development of bispecific fusion proteins, collaborations between pharmaceutical and biotech companies, and advancements in protein engineering.

The rising prevalence of autoimmune disorders is anticipated to drive the growth of the immunoglobulin fusion protein market in the future. Autoimmune disorders are conditions where the body's immune system mistakenly attacks its own healthy cells and tissues. This increasing prevalence is mainly caused by a combination of genetic predisposition and environmental factors, with inherited genes making individuals more vulnerable and triggers such as infections or lifestyle contributing to the onset of these diseases. Immunoglobulin fusion proteins assist in managing autoimmune disorders by modulating the immune response to decrease inflammation and prevent the immune system from attacking the body's tissues. For example, in November 2024, data from Versorgungsatlas.de, a Germany-based organization, indicated that in 2022, out of 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%. Thus, the growing prevalence of autoimmune disorders is fueling the expansion of the immunoglobulin fusion protein market.

Key companies in the immunoglobulin fusion protein market are concentrating on conducting clinical trials to create innovative products like bispecific antibody fusion proteins aimed at improving therapeutic effectiveness and targeting multiple disease pathways. A bispecific antibody fusion protein is a genetically engineered molecule capable of binding two different targets simultaneously, which enhances targeted therapy by bringing immune cells closer to tumor cells or blocking several disease pathways at the same time. For example, in February 2025, Innovent Biologics, Inc., a biotechnology company based in China, received its second Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for IBI343, a bispecific antibody fusion protein aimed at advanced solid tumors. IBI343 is designed to engage tumor-associated antigens and immune effector cells simultaneously, thereby improving the precision and strength of anti-tumor immune responses. This designation is expected to speed up the clinical development and regulatory evaluation of IBI343, highlighting its potential to meet critical unmet medical needs in oncology.

In April 2023, Yuhan Corporation, a pharmaceutical company based in South Korea, acquired Progen Inc. for an undisclosed sum. Through this acquisition, Yuhan Corporation seeks to improve its expertise in developing multi-target antibody therapeutics and to reinforce both domestic and global partnerships by setting up an Open Innovation Center with Progen. Progen Inc. is a South Korean biotechnology firm specializing in immunoglobulin fusion proteins.

Major players in the immunoglobulin fusion protein market are Pfizer Inc., AbbVie Inc., Bayer Aktiengesellschaft, Sanofi S.A., Bristol-Myers Squibb Company, Gilead Sciences Inc., Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Limited, Regeneron Pharmaceuticals Inc., Sobi, 3SBio Inc., Innovent Biologics Inc., Chengdu Kanghong Pharmaceutical Group Co. Ltd., Samsung Bioepis Co. Ltd., Proteintech Group Inc., KRISHGEN Biosystems, Abnova (Taiwan) Corporation, Celgen Biopharma Inc., Chimerigen Laboratories LLC

North America was the largest region in the immunoglobulin fusion proteins market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in immunoglobulin fusion protein report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the immunoglobulin fusion protein market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The immunoglobulin fusion protein market consists of sales of etanercept, abatacept, aflibercept, alefacept, and rilonacept. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Immunoglobulin Fusion Protein Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on immunoglobulin fusion protein market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for immunoglobulin fusion protein ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The immunoglobulin fusion protein market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Monoclonal Antibodies; Polyclonal Antibodies; Bispecific Antibodies; Recombinant Antibodies
• 2) By Drug Class: Immunosuppressive Drugs; Immunostimulatory Drugs
• 3) By Mode of Administration: Intravenous; Subcutaneous; Intramuscular
• 4) By Application: Autoimmune Disease; Eye Diseases; Diabetes; Hemophilia
• 5)By End User: Hospitals; Clinics; Research Institutes
• Subsegments:
• 1) By Monoclonal Antibodies: Human Monoclonal Antibodies; Humanized Monoclonal Antibodies; Chimeric Monoclonal Antibodies; Murine Monoclonal Antibodies
• 2) By Polyclonal Antibodies: Animal-Derived Polyclonal Antibodies; Human-Derived Polyclonal Antibodies; Recombinant Polyclonal Antibodies
• 3) By Bispecific Antibodies: Tandem Single-Chain Variable Fragment; Dual-Variable Domain Antibodies; Bispecific T-Cell Engagers (BiTEs); Dual-Affinity Re-Targeting Antibodies
• 4) By Recombinant Antibodies: Fragment Antibodies; Full-Length Recombinant Antibodies; Antibody-Drug Conjugates (ADCs); Engineered Antibody Domains
• Companies Mentioned: Pfizer Inc.; AbbVie Inc.; Bayer Aktiengesellschaft; Sanofi S.A.; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Immunoglobulin Fusion Protein Market Characteristics

3. Immunoglobulin Fusion Protein Market Trends And Strategies

4. Immunoglobulin Fusion Protein Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Immunoglobulin Fusion Protein Growth Analysis And Strategic Analysis Framework

• 5.1. Global Immunoglobulin Fusion Protein PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Immunoglobulin Fusion Protein Market Growth Rate Analysis
• 5.4. Global Immunoglobulin Fusion Protein Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Immunoglobulin Fusion Protein Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Immunoglobulin Fusion Protein Total Addressable Market (TAM)

6. Immunoglobulin Fusion Protein Market Segmentation

• 6.1. Global Immunoglobulin Fusion Protein Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Polyclonal Antibodies
• Bispecific Antibodies
• Recombinant Antibodies
• 6.2. Global Immunoglobulin Fusion Protein Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunosuppressive Drugs
• Immunostimulatory Drugs
• 6.3. Global Immunoglobulin Fusion Protein Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Subcutaneous
• Intramuscular
• 6.4. Global Immunoglobulin Fusion Protein Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autoimmune Disease
• Eye Diseases
• Diabetes
• Hemophilia
• 6.5. Global Immunoglobulin Fusion Protein Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Research Institutes
• 6.6. Global Immunoglobulin Fusion Protein Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Human Monoclonal Antibodies
• Humanized Monoclonal Antibodies
• Chimeric Monoclonal Antibodies
• Murine Monoclonal Antibodies
• 6.7. Global Immunoglobulin Fusion Protein Market, Sub-Segmentation Of Polyclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Animal-Derived Polyclonal Antibodies
• Human-Derived Polyclonal Antibodies
• Recombinant Polyclonal Antibodies
• 6.8. Global Immunoglobulin Fusion Protein Market, Sub-Segmentation Of Bispecific Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tandem Single-Chain Variable Fragment
• Dual-Variable Domain Antibodies
• Bispecific T-Cell Engagers (BiTEs)
• Dual-Affinity Re-Targeting Antibodies
• 6.9. Global Immunoglobulin Fusion Protein Market, Sub-Segmentation Of Recombinant Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fragment Antibodies
• Full-Length Recombinant Antibodies
• Antibody-Drug Conjugates (ADCs)
• Engineered Antibody Domains

7. Immunoglobulin Fusion Protein Market Regional And Country Analysis

• 7.1. Global Immunoglobulin Fusion Protein Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Immunoglobulin Fusion Protein Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Immunoglobulin Fusion Protein Market

• 8.1. Asia-Pacific Immunoglobulin Fusion Protein Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Immunoglobulin Fusion Protein Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Immunoglobulin Fusion Protein Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Immunoglobulin Fusion Protein Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Immunoglobulin Fusion Protein Market

• 9.1. China Immunoglobulin Fusion Protein Market Overview
• 9.2. China Immunoglobulin Fusion Protein Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Immunoglobulin Fusion Protein Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Immunoglobulin Fusion Protein Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Immunoglobulin Fusion Protein Market

• 10.1. India Immunoglobulin Fusion Protein Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Immunoglobulin Fusion Protein Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Immunoglobulin Fusion Protein Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Immunoglobulin Fusion Protein Market

• 11.1. Japan Immunoglobulin Fusion Protein Market Overview
• 11.2. Japan Immunoglobulin Fusion Protein Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Immunoglobulin Fusion Protein Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Immunoglobulin Fusion Protein Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Immunoglobulin Fusion Protein Market

• 12.1. Australia Immunoglobulin Fusion Protein Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Immunoglobulin Fusion Protein Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Immunoglobulin Fusion Protein Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Immunoglobulin Fusion Protein Market

• 13.1. Indonesia Immunoglobulin Fusion Protein Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Immunoglobulin Fusion Protein Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Immunoglobulin Fusion Protein Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Immunoglobulin Fusion Protein Market

• 14.1. South Korea Immunoglobulin Fusion Protein Market Overview
• 14.2. South Korea Immunoglobulin Fusion Protein Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Immunoglobulin Fusion Protein Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Immunoglobulin Fusion Protein Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Immunoglobulin Fusion Protein Market

• 15.1. Western Europe Immunoglobulin Fusion Protein Market Overview
• 15.2. Western Europe Immunoglobulin Fusion Protein Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Immunoglobulin Fusion Protein Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Immunoglobulin Fusion Protein Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Immunoglobulin Fusion Protein Market

• 16.1. UK Immunoglobulin Fusion Protein Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Immunoglobulin Fusion Protein Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Immunoglobulin Fusion Protein Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Immunoglobulin Fusion Protein Market

• 17.1. Germany Immunoglobulin Fusion Protein Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Immunoglobulin Fusion Protein Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Immunoglobulin Fusion Protein Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Immunoglobulin Fusion Protein Market

• 18.1. France Immunoglobulin Fusion Protein Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Immunoglobulin Fusion Protein Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Immunoglobulin Fusion Protein Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Immunoglobulin Fusion Protein Market

• 19.1. Italy Immunoglobulin Fusion Protein Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Immunoglobulin Fusion Protein Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Immunoglobulin Fusion Protein Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Immunoglobulin Fusion Protein Market

• 20.1. Spain Immunoglobulin Fusion Protein Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Immunoglobulin Fusion Protein Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Immunoglobulin Fusion Protein Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Immunoglobulin Fusion Protein Market

• 21.1. Eastern Europe Immunoglobulin Fusion Protein Market Overview
• 21.2. Eastern Europe Immunoglobulin Fusion Protein Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Immunoglobulin Fusion Protein Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Immunoglobulin Fusion Protein Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Immunoglobulin Fusion Protein Market

• 22.1. Russia Immunoglobulin Fusion Protein Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Immunoglobulin Fusion Protein Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Immunoglobulin Fusion Protein Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Immunoglobulin Fusion Protein Market

• 23.1. North America Immunoglobulin Fusion Protein Market Overview
• 23.2. North America Immunoglobulin Fusion Protein Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Immunoglobulin Fusion Protein Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Immunoglobulin Fusion Protein Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Immunoglobulin Fusion Protein Market

• 24.1. USA Immunoglobulin Fusion Protein Market Overview
• 24.2. USA Immunoglobulin Fusion Protein Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Immunoglobulin Fusion Protein Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Immunoglobulin Fusion Protein Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Immunoglobulin Fusion Protein Market

• 25.1. Canada Immunoglobulin Fusion Protein Market Overview
• 25.2. Canada Immunoglobulin Fusion Protein Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Immunoglobulin Fusion Protein Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Immunoglobulin Fusion Protein Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Immunoglobulin Fusion Protein Market

• 26.1. South America Immunoglobulin Fusion Protein Market Overview
• 26.2. South America Immunoglobulin Fusion Protein Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Immunoglobulin Fusion Protein Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Immunoglobulin Fusion Protein Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Immunoglobulin Fusion Protein Market

• 27.1. Brazil Immunoglobulin Fusion Protein Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Immunoglobulin Fusion Protein Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Immunoglobulin Fusion Protein Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Immunoglobulin Fusion Protein Market

• 28.1. Middle East Immunoglobulin Fusion Protein Market Overview
• 28.2. Middle East Immunoglobulin Fusion Protein Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Immunoglobulin Fusion Protein Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Immunoglobulin Fusion Protein Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Immunoglobulin Fusion Protein Market

• 29.1. Africa Immunoglobulin Fusion Protein Market Overview
• 29.2. Africa Immunoglobulin Fusion Protein Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Immunoglobulin Fusion Protein Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Immunoglobulin Fusion Protein Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Immunoglobulin Fusion Protein Market Competitive Landscape And Company Profiles

• 30.1. Immunoglobulin Fusion Protein Market Competitive Landscape
• 30.2. Immunoglobulin Fusion Protein Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Immunoglobulin Fusion Protein Market Other Major And Innovative Companies

• 31.1. Gilead Sciences Inc.
• 31.2. Eli Lilly and Company
• 31.3. Amgen Inc.
• 31.4. Teva Pharmaceutical Industries Limited
• 31.5. Regeneron Pharmaceuticals Inc.
• 31.6. Sobi
• 31.7. 3SBio Inc.
• 31.8. Innovent Biologics Inc.
• 31.9. Chengdu Kanghong Pharmaceutical Group Co. Ltd.
• 31.10. Samsung Bioepis Co. Ltd.
• 31.11. Proteintech Group Inc.
• 31.12. KRISHGEN Biosystems
• 31.13. Abnova (Taiwan) Corporation
• 31.14. Celgen Biopharma Inc.
• 31.15. Chimerigen Laboratories LLC

32. Global Immunoglobulin Fusion Protein Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Immunoglobulin Fusion Protein Market

34. Recent Developments In The Immunoglobulin Fusion Protein Market

35. Immunoglobulin Fusion Protein Market High Potential Countries, Segments and Strategies

• 35.1 Immunoglobulin Fusion Protein Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Immunoglobulin Fusion Protein Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Immunoglobulin Fusion Protein Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer